The impact of health technology made simple...

...from the implications of new medical procedures, technologies and policies...

...to measuring their impact on current clinical practices...

...through close collaboration with health care professionals, researchers, and regulators.

Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.

  • Real World Economic Analysis

  • Market Research and Access

  • Horizon Scanning

  • Branding

  • Communications

Contact us to learn how Vital Transformation can help your organisation.

LATEST RESEARCH

The Economic Pandemic: Aggressive Testing Is Vital to Controlling the Spread of COVID19 and Saving Europe’s Economy

For the last month, a debate has raged over which approach to managing the spread of COVID-19 is correct. One aspect of this debate is about the efficacy of widespread testing. South Korea and Germany have pursued aggressive testing. The Netherlands, Sweden, and the UK – at least initially – limited testing and instead sought to create herd immunity by letting the virus run its course. Which approach is better? Given the implications of getting the choice wrong, opinions towards both approaches have been strong and vociferous. Adding to the confusion, experts disagree about which of many variables are more important for explaining higher rates of morbidity from COVID19. These include the percent of a population over 65 years of age, the case fatality rate, the population density of a region, the availability of hospital beds and ventilators per 1000 population, rates of tourism, usage of public transport, and number of university students in a given area to name a few.

LATEST COMMUNICATIONS

Our Communication Services

Webinar:
Cancer and COVID-19
“Short Term Reality, Long-term Vision”
4 May, 11.30-12.30 CEST

Access to cancer care and treatments has become an issue because of the pandemic. Why is this the case, and what does the current situation mean for cancer patients in terms of access to care, new medicines, and timely diagnosis? And in the longer run: What will be the impact on Europe’s Beating Cancer Plan?

Watch the video of this webinar organised by the EFPIA Oncology Platform

Video

Find all our communication projects on Better Science, Better Health

MORE RESEARCH

Insulin prices and pharmacy benefit manager rebates: pin the tail on the patient

19 March 2020



What's the impact of Pharmaceutical Benefit Managers on US Insulin prices? In researching HR3, Vital Transformation found $2 bil in 'lost' revenue reported in Medicare Part D, but missing in audited actual sales on company balance sheets. Time to bring back the Rebate Rule?

Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&D

26th November 2019



According to Secretary Azar of Health and Human Services, implementing international reference pricing (IPI) in Medicare Part B will have minimal impacts. He has stated, “These savings, while substantial for American patients and taxpayers, cannot possibly pull out more than 1 percent of R&D.” As companies traditionally spend 20% of free cash flow on R&D, we have measured the IPI impact according to industry standard metrics.

International Reference Pricing Under H.R.3 Would Devastate the Emerging Biotechnology Sector, Leading to 56 Fewer New Medicines Coming to Market Over 10 Years

Vital Transformation projected the impact that utilizing international reference pricing for retail medicines (as proposed as part of the Lower Drug Costs Now Act of 2019, H.R.3) would have on the innovative biotechnology sector in the U.S. While the industry revenue reductions resulting from H.R.3 would harm industry innovation across the board, the analysis found that it would have an especially large impact on small, emerging biotech firms that rely on venture capital and revenue streams from the rest of the industry to finance their R&D investments. The result will be fewer medicines coming to market and available to patients.

VITAL HEALTH PODCASTS

SUBSCRIBE

NEWSLETTER

Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…

Sign Up

TWEETS

Our clients include many of the world’s leading health care organisations.